Table 2 Completed CD19 CAR-T clinical trials for B-cell non-Hodgkin lymphoma
From: Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
NCT Number | Phase | Status | Locations | Clinical outcomes |
|---|---|---|---|---|
NCT01593696 | Phase I | Completed | National Institutes of Health Clinical Center, 9000 RockvillePike, Bethesda, Maryland, United States | The CR rate was 59.6% (31/52). The occurrence rate of serious adverse events and high grade CRS were 26.9% (14/52) and 9.6% (5/52). |
NCT02132624 | Phase I / IIa | Completed | Uppsala University Hospital, Dept of Oncology, Uppsala,Sweden | Six of the 15 patients had complete responses (4/11 lymphoma and 2/4 ALL). Three patients developed severe CRS in 15 patients and 2 patients developed high grade ICANS. |
NCT02030834 | Phase IIa | Completed | Abramson Cancer Center of the University of Pennsylvania,Philadelphia, Pennsylvania, United States | The objective response rate was 64% (18/28). Occurrence rate of serious CRS and ICANS were 18% (5/28) and 11% (3/28) |
NCT01626495 | Phase I /IIa | Completed | CHOP-http://www.chop.edu/service/oncology/pediatric-cancer-research/cart-19-trial.html, Philadelphia, Pennsylvania, UnitedStates | The CR rate was 25.8% (16/62) and CRi (complete remission with incomplete blood count recovery) rate was 61.3% (38/62). |